Design and statistical optimization of effervescent floating drug delivery system of theophylline using response surface methodology by VENKATA SRIKANTH MEKA et al.
35
Acta Pharm. 66 (2016) 35–51 Original research paper
DOI: 10.1515/acph-2016-0002
Design and statistical optimization of an eff ervescent fl oating 
drug delivery system of theophylline using response surface 
methodology
The aim of this research was to formulate eff ervescent fl oat-
ing drug delivery systems of theophylline using diff erent 
release retarding polymers such as ethyl cellulose, Eudragit® 
L100, xanthan gum and polyethylene oxide (PEO) N12K. So-
dium bicarbonate was used as a gas generating agent. Direct 
compression was used to formulate fl oating tablets and the 
tablets were evaluated for their physicochemical and disso-
lution characteristics. PEO based formulations produced 
bett er drug release properties than other formulations. 
Hence, it was further optimized by central composite de-
sign. Further subjects of research were the eff ect of formula-
tion variables on fl oating lag time and the percentage of 
drug released at the seventh hour (D7h). The optimum quan-
tities of PEO and sodium bicarbonate, which had the highest 
desirability close to 1.0, were chosen as the statistically opti-
mized formulation. No interaction was found between the-
ophylline and PEO by Fourier Transformation Infrared spec-
troscopy (FTIR) and Diff erential Scanning Calorimetry 
(DSC) studies.
Keywords: theophylline, gastroretentive, fl oating, central 
composite, PEO N12K
An oral controlled-release drug delivery system allows less frequent dosing and in-
creased patient compliance (1, 2). However, these drug delivery systems usually have a 
short gastric residence time, leading to poor bioavailability and incomplete drug absorp-
tion (3, 4).
Gastroretentive drug delivery systems (GRDDS) off er an alternative approach to avoid 
such diffi  culties and might provide a bett er therapeutic action than other drug delivery 
systems (5). Prolonged gastric retention enhances bioavailability, reduces drug waste and 
improves the solubility of drugs that are less soluble in a high pH environment. GRDDS 
limit fl uctuations of plasma drug concentrations (6–8). This feature is vital for drugs such 
as theophylline, which have a narrow therapeutic window.
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In this study, theophylline is used as a model drug for the development of GRDDS. 
Theophylline is a bronchodilator used in moderate to severe reversible bronchospasms 
and in stable chronic obstructive pulmonary disease. It is a narrow therapeutic window 
drug (plasma concentration between 10–20 mg L–1), which requires therapeutic drug moni-
toring (9, 10). Theophylline is mainly metabolized in the liver and has an elimination half-
life of 6 hours (11). It has a good absorption window in the upper gastrointestinal tract, 
making it suitable for GRDDS. Eff ervescent fl oating tablets of theophylline have been de-
veloped in order to increase drug effi  cacy, to minimize fl uctuation of drug plasma concen-
tration and to reduce concentration-dependent adverse eff ects (12, 13).
In this study, an eff ervescent fl oating drug delivery system of theophylline was pre-
pared using release retarding polymers such as ethyl cellulose, Eudragit® L100, xanthan 
gum and polyethylene oxide (PEO) N12K. Sodium bicarbonate was used as a gas generating 
agent. Ethyl cellulose and PEO N12K are hydrophobic and hydrophilic polymers, respec-
tively (12, 13). Eudragit® is an anionic copolymer, whereas xanthan gum is a complex exo-
polysaccharide produced by Xanthomonas campestris (14, 15). The selected polymers have 
good swelling properties (5). When in contact with gastric fl uid, polymers will form a vis-
cous matrix and retard the release of the drug from the system (16). When in contact with 
gastric fl uid, sodium bicarbonate will liberate carbon dioxide gas (16, 17). The gas entrapped 
within the matrix decreases the density of the tablet below 1 g cm–3, providing buoyancy to 
the dosage form (16, 18). While the system is fl oating in the gastric medium, the drug will 
be released slowly at a controlled rate without aff ecting the gastric emptying rate (7, 19).
Based on previous studies, the fl oating lag time was signifi cantly controlled by the 
quantity of sodium bicarbonate (20). The total polymer-to-polymer ratio and drug-to-poly-
mer ratio signifi cantly aff ected the drug release properties and total fl oating time (21).
The conventional optimization process allows only a single independent variable to 
be altered at a time, while other parameters remain constant under a specifi c set of condi-
tions during formulation development (22). This results in the requirement for a large 
number of runs to achieve target responses (18). A statistical approach using response 
surface methodology (RSM) can be employed to optimize the formulation using a suitable 
experimental design such as central composite design (23). RSM reduces the cost of con-
ducting analytical studies, limits random errors and predicts accurate quantities of the 
polymers to achieve the target formulation (23, 24).
The objective of the present study was to formulate an eff ervescent fl oating drug de-
livery system of theophylline using the gas generating agent sodium bicarbonate and re-
lease retarding polymers such as ethyl cellulose, Eudragit® L100, xanthan gum and PEO 
N12K. Other objectives included optimization of the formulation of theophylline by apply-
ing a statistical approach using a central composite design and examining the eff ect of 
formulation variables on the dependent variables.
EXPERIMENTAL
Materials
Ethyl cellulose and PEO N12K were obtained as gift  samples from Colorcon Asia Pa-
cifi c Ltd, Singapore. Eudragit® L 100 was obtained as a gift  sample from Jebsen & Jessen 
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Chemicals, Malaysia. Sodium bicarbonate was purchased from Ajax Finechem, Malaysia. 
Theophylline, xanthan gum, microcrystalline cellulose, lactose, d-mannitol min. 98 %, talc 
and magnesium stearate were purchased from Labchem Sdn Bhd, Malaysia.
Conventional formulation optimization
Twelve diff erent formulations with varying quantities of diff erent polymers were se-
lected for the development of gastroretentive fl oating tablets (GRFT) of theophylline (Table I). 
The tablets were subjected to physicochemical tests and in vitro studies as described below.
Preparation of eff ervescent fl oating tablets of theophylline
All the ingredients were passed through a 500 μm sieve. Theophylline was homoge-
nously mixed in geometrical ratio with the release retarding polymer, followed by sodium 
bicarbonate, diluent, talc and magnesium stearate. 1 % of talc and magnesium stearate 
were used in all the formulations.
Table I. Working formulae of theophylline GRFT developed conventionally
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B1 50 30 – – – 10 106 – – 2 2 200
B2 50 30 – – – 30 – 86 – 2 2 200
B3 50 15 – – – 30 – 101 – 2 2 200
B4 50 50 – – – 40 – – 56 2 2 200
B5 50 – 30 – – 30 – – 86 2 2 200
B6 50 – 50 – – 40 – – 56 2 2 200
B7 50 – 100 – – 40 – – 6 2 2 200
B8 50 – 150 – – 40 – – 6 2 2 200
B9 50 – – 75 – 20 – – 51 2 2 200
B10 50 – – – 50 20 – – 76 2 2 200
B11 50 – – – 75 20 – – 51 2 2 200
B12 50 – – – 90 20 – – 36 2 2 200
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The fi nal blend was directly compressed into tablets with a 10-station rotary tablet 
punching machine (Rimek Mini Press-I) at a hardness of 3–4 kg cm–2. Round fl at punches 
of 8.0 mm die size were used. Fift y tablets were produced for each formulation.
Evaluation of fl oating tablets
All fl oating tablets were evaluated for physicochemical parameters as described be-
low.
Mass variation test. – Twenty randomly chosen tablets were weighed individually. Each 
tablet mass was compared with the average mass to determine if it was within the accep-
tance limits. 200 mg ± 7.5 % is the percentage deviation allowed for a tablet weighing 200 
mg (25).
 mass variation (%) = 100
average mass – mass of individual tablet
average mass
×
Hardness test. – The hardness of ten randomly chosen tablets was measured using a 
Monsanto hardness tester (T-MMT-20, Tab machines, India). The fracture load (kg cm–2) of 
ten tablets was determined individually to check tablet hardness, also represented as ten-
sile strength. The mean values of fracture loads were used to calculate the hardness values.
Thickness test. – Twenty tablets were subjected to thickness testing using Mitutoyo 
vernier calipers (Model: 530-312, Japan). A thickness deviation within ± 5 % was allowed.
Friability test. – The friability test was performed using a Friabilator (Electrolab, Model: 
EF-2, India). Twenty pre-weighed tablets were placed in the rotating drum, which was 
subjected to 100 revolutions. The tablets were reweighed aft er rotations. The percentage 
mass loss should not be more than 1 % of total weight (26).
Content uniformity. – Ten randomly chosen tablets were powdered in a glass mortar 
and 50 mg of powder was transferred into a 100 mL volumetric fl ask. The powder was dis-
solved in 30 mL of methanol and made up to 100 mL with 0.1 mol L–1 HCl. The solution was 
fi ltered and 3 mL of fi ltrate was extracted and made up to 100 mL with 0.1 mol L–1 HCl. The 
concentration of theophylline was determined with a validated UV spectrophotometer 
(LAMBDA 25, Perkin Elmer) at 270 nm.
In vitro buoyancy studies
All the formulated tablets (n = 6) were subjected to in vitro buoyancy studies. The fl oat-
ing lag time was determined in a 1 L glass beaker containing 900 mL 0.1 mol L–1 HCl. The 
time required for the tablet to fl oat was determined as the fl oating lag time. A fl oating lag 
time of less than 1 minute is desirable.
In vitro dissolution studies
In vitro release of theophylline (n = 6) was studied using an Electrolab TDT-08L dis-
solution tester (USP) employing a paddle stirrer. 900 mL of 0.1 mol L–1 HCl solution was 
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maintained at 37 ± 0.5 °C at a paddle speed of 100 rpm. 5-mL aliquots were withdrawn at 
specifi c time intervals using a syringe fi tt ed with a 0.45 μm pre-fi lter and were immedi-
ately replaced with 5 mL of fresh dissolution medium. Each aliquot was fi ltered and di-
luted when necessary. The samples were analyzed using a UV spectrophotometer at 270 
nm. The in vitro dissolution studies were triplicated for all batches (18).
Formulation optimization using experimental design
A central composite design was employed using the Design-Expert (7.1.6) soft ware. 
The design contained two factors evaluated at two levels. The levels of two independent 
variables are shown below. Nine diff erent formulations were generated by the soft ware 
based on the conventionally optimized formulation (Table III). Tablets were prepared and 
characterized in the same manner as conventionally developed tablets. The formulation 
variables evaluated included:
Variables
Range and levels
–1 0 +1
PEO WSR N12K (mg) X1 70 90 110
Sodium bicarbonate ratio X2 (%, m/m) 5 10 15
X1 = A = Amount of PEO N12K (mg)
X2 = B = Percentage of sodium bicarbonate (%)
The response variables included:
Y1 = Floating lag time (s)
Y2 = D7h (percentage of drug released at 7th h) (%)
Statistical analysis and optimization
Polynomial models including linear, interaction and quadratic terms were generated 
for all the response variables using the Design-Expert soft ware. The best fi tt ing model was 
selected by comparing the coeffi  cient of variation (CV), adjusted coeffi  cient of determina-
tion (adjusted R2), the coeffi  cient of determination (R2) and the predicted residual sum of 
squares (PRESS) provided by the soft ware. Regression coeffi  cients test, F and P values were 
calculated by the soft ware. Analysis of variance (ANOVA) showed the eff ect of factors on 
the responses.
Release kinetics
The dissolution profi les of all statistically formulated batches were fi tt ed to the zero 
order, fi rst order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas. The order and mecha-
nism of drug release from the matrix system were determined based on high regression 
(R2) values (19).
40
V. Srikanth Meka et al.: Design and statistical optimization of an eff ervescent fl oating drug delivery system of theophylline using 
response surface methodology, Acta Pharm. 66 (2016) 35–51.
 
The data were evaluated based on the following equations:
Zero order release kinetics: Qt = Q0 + k0 t
First order release kinetics: log M = log M0 – k1 t/2.303
Higuch i model: Q = kH t1/2
Hixson-Crowell cube root model (erosion): W01/3 – Wt1/3 = KHC t
Korsmeyer-Peppas model: Mt/M∞ = kp tn
where, Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution, M0 is the initial concentration of drug in the dosage form, M is the remaining 
amount of drug in the dosage form, W0 is the initial amount of drug in the pharmaceutical 
dosage form, Wt is the remaining amount of drug in the pharmaceutical dosage form at 
time t, Mt is the amount of drug released at time t, M∞ is the amount released at time ∞ and 
n is the diff usion exponent. The n value is obtained as a slope by plott ing the log percent-
age drug released against the log time for diff erent batches (12). K0, k1, kH, kHC and kp refer 
to the kinetic constants obtained from the linear curves of the zero order, fi rst order, Hi-
guchi, Hixson-Crowell and Korsmeyer-Peppas, respectively.
Validation of the experimental design
To validate the chosen experimental design, the experimental values of formulation 
responses were quantitatively compared with those of predicted values generated by the 
soft ware. The percentage relative error was calculated by the following equation:
 Relative error (%) = 100
predicted value – observed value
predicted value
×
In vitro buoyancy and dissolution studies of the statistically optimized formulation 
were performed for verifi cation of the theoretical prediction (24).
Drug-excipient interaction studies
Diff erential scanning calorimetry (DSC). – DSC analysis of the drug, polymer and the 
statistically optimized formulation (F0) were done using a diff erential scanning calorim-
eter (Mett ler Toledo DSC 823e). 3–10 mg of the sample was heated under nitrogen atmo-
spheres from 0 to 280 °C at a heating rate of 10 °C/min.
Fourier transformation infrared spectroscopy (FTIR). – The possibility of drug-polymer 
interaction was further investigated by FTIR using the potassium bromide pellet method. 
About 2–3 mg of the sample was ground with 200 mg of potassium bromide and com-
pressed under high pressure to form a transparent disc. The disc was scanned by an IR 
spectrophotometer (Shimadzu, FTIR-8400S) in the region between 4000–650 cm–1.
RESULTS AND DISCUSSION
The results of physicochemical characterization of twelve formulations developed by 
the conventional approach are shown in Table II. Variations of tablet thickness with the 
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Table II. Physicochemical properties and observed responses of the theophylline GRFT developed conventionally
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B1 198 ± 1.50 3–4 3.86 0.39 Does notfl oat 68 ± 0.05
B2 205 ± 1.40 3–4 3.93 0.47 37 63 ± 1.73
B3 200 ± 1.44 3–4 3.90 0.41 40 64 ± 1.34
B4 201 ± 0.83 3–4 3.88 0.16 180 870.08
B5 202 ± 1.60 3–4 3.89 0.05 2 100 ± 0.98(at 4th hour)
B6 204 ± 1.35 3–4 3.92 0.51 3 100 ± 1.22(at 4th hour)
B7 199 ± 1.14 3–4 3.91 0.23 3 90 ± 1.01
B8 196 ± 1.21 3–4 3.84 0.27 20 100 ± 0.69(at 6th hour)
B9 202 ± 1.10 3–4 3.89 0.48 2 84 ± 0.40
B10 200 ± 1.20 3–4 3.89 0.36 2 85 ± 2.48
B11 207 ± 0.97 3–4 3.95 0.30 0.05 83 ± 0.12
B12 203 ± 1.36 3–4 3.90 0.11 0.05 90 ± 1.31
Table III. Working formulae of the theophylline GRFT developed using experimental design
Ingredients (mg) S1 S2 S3 S4 S5 S6 S7 S8 S9
Theophylline 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
PEO N12K 70.00 110.00 70.00 110.00 61.72 118.28 90.00 90.00 90.00
Sodium bicarbonate 10.00 10.00 30.00 30.00 20.00 20.00 5.86 34.14 20.00
d-Mannitol 66.00 26.00 46.00 6.00 64.28 7.72 50.14 21.86 36.00
Talc 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00
Magnesium stearate 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00
Total tablet mass 200 200 200 200 200 200 200 200 200
same tablet mass may be due to the diff erences in the condition of the punches and in the 
speed of tablet compression (27). The fl oating lag time of most of the formulations was 
more than 1 minute, except for B11 and B12 which took 3 seconds to fl oat (Table II).
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The target drug release is about 85–90 % at the end of 8 hours (28). From the dissolu-
tion profi les shown in Fig. 1, ethyl cellulose-based formulations (B1-B3) showed that only 
63–64 % of the drug was released at the end of 8 hours, which was not desirable. B1, B2 and 
B3 had poor matrix integrity. The tablets were completely disintegrated within 4–5 hours 
in the dissolution medium. In B4, where the quantity of sodium bicarbonate was larger 
than in previous batches (B1-B3), tablets took around 3 hours to fl oat in the gastric medium 
and were retarded up to 8 hours. When D-mannitol was used as the diluent in B4, 90 % of 
the drug was released at the end of 8 hours. Hence, D-mannitol is considered as the most 
suitable diluent for formulating theophylline fl oating tablets.
The dissolution profi les of B1-B4 reveal clear diff erentiation of the eff ect of diluents on 
the drug release patt ern. The eff ect of the solubility of the diluent on the drug release pat-
tern was explored. The water-insoluble diluent, microcrystalline cellulose (MCC), signifi -
cantly retarded drug release (B1), with 60–64 % of drug being released at the end of the 
eighth hour. On the other hand, lactose, a water-soluble diluent, showed rapid disintegra-
tion properties; dosage forms using lactose (B2-B3) could not control drug release for more 
than 4 hours. However, another water soluble diluent, mannitol, showed very good retar-
dation properties compared to lactose and MCC. Hence, further compositions used man-
nitol as the diluent.
Ethyl cellulose had poor buoyancy properties. The fl oating lag time of B1-B4 was still 
more than 1 minute, although the percentage of sodium bicarbonate had been increased 
to 40 % and diff erent diluents were used.
Fig. 1. Release profi les of theophylline from the conventionally optimized GRFT: a) B1–B3, b) B4–B6, 
c) B7–B9 and d) B10–B12.
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On the other hand, Eudragit® L100 based formulations (B5-B8) showed a burst release 
patt ern. Eudragit® L100 was not compatible with theophylline, as the tablets completely 
disintegrated within 3-4 minutes in the dissolution medium. Consistent with the previous 
literature, Eudragit® L100 is a good enteric coating polymer (14). However, this polymer is 
not useful for theophylline fl oating drug delivery systems. As the higher density of Eu-
dragit® L100 may have prevented the formulation from fl oating on the gastric medium, the 
sodium bicarbonate concentration was increased to 10–30 % (m/m) to improve the buoy-
ancy properties; however, this made the dosage form disintegrate rapidly. Therefore, a 
continuous fl oating system with prolonged release could not be achieved using Eudragit® 
L100 polymer (14).
PEO N12K and xanthan gum based formulations showed good drug release patt erns 
and good matrix integrity. However, the xanthan gum-based formulation had poor buoy-
ancy. Formulations based on PEO N12K were shown to be readily swellable in the gastric 
fl uid, thus the tablets were buoyant in less than 1 minute (12). However, formulations con-
taining less than 50 mg xanthan gum disintegrated rapidly in the dissolution medium (12).
Ethyl cellulose has the highest drug retarding ability compared to PEO N12K and 
xanthan gum, whereas Eudragit® L100 has the least retarding ability. Drug retarding abil-
ity is aff ected by the molecular weight of the polymer (18). Higher molecular weight poly-
mers retarded the drug more effi  ciently than polymers with lower molecular weight (12). 
Based on the present results, PEO N12K appeared to be the best polymer for formulating 
theophylline eff ervescent fl oating tablets. Therefore, B12 was further optimized by central 
composite design.
Table IV. Physicochemical properties and observed responses of the theophylline GRFT developed using 
experimental design
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S1 70.00 5.00 201 ± 1.20 3.9 ± 0.01 3.91 0.31 ± 0.01 25 87.50 ± 0.67
S2 110.00 5.00 209 ± 1.47 3.8 ± 0.04 3.97 0.24 ± 0.02 45 74.50 ± 1.10
S3 70.00 15.00 199 ± 1.36 4.1 ± 0.02 3.86 0.26 ± 0.04 5 75.90 ± 2.12
S4 110.00 15.00 210 ± 1.13 4.2 ± 0.11 3.98 0.17 ± 0.06 7 69.10 ± 0.72
S5 61.72 10.00 202 ± 1.45 3.4 ± 0.06 3.92 0.43 ± 0.07 4 83.80 ± 0.70
S6 118.28 10.00 201 ± 1.42 3.8 ± 0.04 3.90 0.40 ± 0.08 17 81.10 ± 0.57
S7 90.00 2.93 198 ± 1.63 3.5 ± 0.05 3.87 0.12 ± 0.04 11 89.78 ± 0.77
S8 90.00 17.07 205 ± 1.34 4.0 ± 0.01 3.94 0.46 ± 0.05 3 82.24 ± 0.02
S9 90.00 10.00 196 ± 1.91 4.1 ± 0.03 3.85 0.38 ± 0.01 6 90.50 ± 1.17
44
V. Srikanth Meka et al.: Design and statistical optimization of an eff ervescent fl oating drug delivery system of theophylline using 
response surface methodology, Acta Pharm. 66 (2016) 35–51.
 
Fig. 2. Release profi les of theophylline from the statistically optimized theophylline GRFT: a) S1–S3, 
b) S4–S6 and c) S7–S9.
Table V. Correlation coeffi  cient values and release kinetics of the statistically optimized theophylline GRFT
Formu-
lation
Zero
order
First
order Higuchi
Hixson-
Crowell
Korsmeyer-
Peppas
R2 Slope (n) R2 Slope(n) R2 R2 R2 Slope (n)
S1 0.9463 11.425 0.9558 –0.1218 0.9562 0.9636 0.9918 0.8261
S2 0.9908 10.181 0.9871 –0.0893 0.9608 0.9978 0.9991 0.8606
S3 0.9880 10.361 0.9903 –0.0904 0.9544 0.9969 0.9964 0.9070
S4 0.9926 9.4671 0.9871 –0.0742 0.9500 0.9959 0.9970 0.9611
S5 0.9466 10.344 0.9975 –0.1075 0.9884 0.9927 0.9602 0.6047
S6 0.9935 11.153 0.9736 –0.1099 0.9493 0.9927 0.9963 0.8893
S7 0.9776 11.861 0.9743 –0.1392 0.9626 0.9906 0.9955 0.8406
S8 0.9870 11.139 0.9801 –0.1068 0.9510 0.9942 0.9972 1.0303
S9 0.9784 11.821 0.9706 –0.149 0.9713 0.9952 0.9858 0.7386
F0 0.9987 12.455 0.7764 –0.202 0.9217 0.9358 0.9961 0.9657
All nine formulations satisfi ed the criteria of the physicochemical tests (Table IV). The 
fl oating lag time of S1-S9 was within 3 to 45 seconds. As the percentage of sodium bicar-
bonate increased, the fl oating lag time decreased. On the other hand, as the amount of PEO 
N12K increased, the fl oating lag time increased.
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Based on the dissolution profi les, only the S7 and S9 formulations showed more than 
90 % drug release by the end of 8 hours. Other formulations required more than 8 hours 
to achieve 100 % drug release. Drug retardation was directly proportional to the quantity 
of PEO N12K because of the formation of strong compactness between the particles when 
the concentration of polymer was higher (Table IV). All statistical formulations fl oated in 
the dissolution medium for more than 8 hours and showed good matrix integrity (Fig. 2).
Most PEO N12K based formulations followed zero order kinetics associated with the 
erosion mechanism (Table V), which obeyed the rule of a controlled drug delivery system. 
S1, S3 and S5 formulations followed fi rst order kinetics associated with the erosion mech-
anism. Release mechanisms changed from fi rst order to zero order kinetics as the amount 
of PEO N12K exceeded 70 mg.
From the polynomial model fi tt ing statistical analysis, fl oating lag time and D7h were 
suggested to linear model. Calculated R2 values for both the fl oating lag time and D7h were 
close to zero, which was ideal for a good model. Results are shown in Table VI.
The application of response surface methodology yielded the following regression 
equations, which are an empirical relationship between the logarithmic values of the fl oat-
ing lag time and D7h.Test variables in coded units:
 Floating lag time = +13.67 + 5.05A – 8.66B
 D7h = +81.60 – 2.95A – 3.46B
Contour and response plots shown in Figs. 3 and 4 allowed more understanding of the 
relationship of two parameters at the time of formulation responses.
A numerical optimization technique using a desirability approach (bilateral) and a 
graphical optimization method using overlay plot (Fig. 5) were employed to generate op-
timized formulations with the desired characteristics. The optimized formulation was 
selected based on a minimal fl oating lag time, release of less than 20 % of the drug in the 
fi rst hour, and a D7h of 90 %. The recommended quantities of independent variables were 
calculated using the Design-Expert soft ware based on the plots showing the highest desir-
ability of 1.0. The optimum values of independent variables calculated by the soft ware for 
the development of a GRFT of theophylline were 88.97 mg of PEO N12K and 10.46 % of 
sodium bicarbonate.
Fig. 3. Contour plots for the eff ect of: a) PEO N12K and b) sodium bicarbonate on fl oating lag time and D7h.
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F0 fulfi lled all the physicochemical property tests (Table VII). In vitro buoyancy and 
dissolution studies of F0 were performed for verifi cation of the theoretical prediction. In 
vitro studies of F0 showed an ideal result. The data from the assay indicated that the sta-
tistically optimized formulation had a drug content within the USP limits, between 97.34 
and 98.76 %. Percentage relative errors for fl oating lag time and D7h were 0 and 0.54 % re-
spectively, which were within 5 %, hence showing close agreement with the model predic-
tions; we confi rmed the predictability and validity of F0.
Drug-excipient interactions were studied by DSC and FTIR. DSC thermograms of 
theophylline, PEO N12K and F0 are shown in Fig. 6. The DSC thermogram of theophylline 
showed a sharp endothermic peak at 273 °C that corresponded to its melting point. The 
Fig. 5. Overlay plot for optimization of the theophylline GRFT.
Fig. 4. Response surface plots for the eff ect of: a) PEO N12K and b) sodium bicarbonate on fl oating lag 
time and D7h.
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Table VI. Summary of ANOVA results for the response surface linear model
Parameters Sum of squares dF
Mean 
square F value
p value 
Prob > F Remark
Response 1: Floating lag time (s) (Linear model)
Model 804.42 2 402.21 3.40 0.1030 –
A-PEO N12K 203.87 1 203.87 1.72 0.2372
B-Sodium 
bicarbonate 600.55 1 600.55 5.08 0.0651
Residual 709.58 6 118.26
Cor total 1514.00 8
Response 2: D7h (%) (Linear model)
Model 165.38 2 82.69 1.91 0.2285 –
A-PEO N12K 69.73 1 69.73 1.61 0.2518
B-Sodium 
bicarbonate 95.66 1 95.66 2.21 0.1880
Residual 260.20 6 43.37
Cor total 425.58 8
Fig. 6. DSC thermogram of: a) theophylline, b) PEO N12K and c) F0.
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Fig. 7. FTIR spectra of: a) theophylline, b) PEO N12K and c) F0.
Table VII. Tableting and buoyancy characteristics of optimized formulation F0
Statistically 
optimized 
formulation
Tableting characteristics Buoyancy characteristics
Mass
(mg)
Hardness
(kg cm–2)
Thickness
(mm)
Friability 
(%)
Assay
(%)
Floating 
lag time 
(s)
Percentage drug 
released at 7th h, 
D7h (%)
F0 200 ± 0.12 3–4 4.6 0.42 98.045 ± 0.79 5 89.78 ± 0.87
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DSC thermogram of PEO N12K showed an endothermic peak at 70.92 and an exothermic 
peak at 172 °C.
Based on the F0 thermogram, the peaks observed at 272.1, 70 and 170.9 °C corresponded 
to the peaks of the drug and the polymer. Slight decreases in the melting points were due 
to the crystallinity of the drug. The absence of any major changes in the F0 DSC thermo-
gram indicated that there was no chemical reaction between the drug and the polymer.
The FTIR spectra of theophylline, PEO N12K and F0 are shown in Fig. 7. Theophylline 
showed characteristic peaks of C=O stretching at 1716.7–1668.48, N-H stretching at 3387.11–
3261.74, C=N stretching at 1568.69, C=C stretching at 1820.86 and C-N stretching at 1313.57–
1284.63 cm–1. The FTIR spectrum of PEO N12K showed characteristic peaks of alcoholic 
OH stretching broadly at 3464.27–3437.26 and C-O stretching at 1301.99–1003.02 cm–1.
The FTIR spectrum of F0 showed all the characteristics peaks of theophylline and 
PEO N12K with minor shift s, which were not signifi cant. This proved the absence of drug-
polymer interactions.
CONCLUSIONS
The present study successfully indicated the capability of using the release retarding 
polymer PEO N12K to formulate eff ervescent tablets of theophylline that can fl oat con-
tinuously in the gastric medium and release drug in a controlled manner for 8 hours. The 
study has also proved that optimization using a statistical approach can reduce the num-
ber of experiments required to determine accurately the quantities of polymer and sodium 
bicarbonate to produce the desired tablet characteristics, avoiding unnecessary wastage of 
excipients and thereby reducing the cost of the fi nal product. DSC and FTIR studies 
showed no chemical interaction between theophylline and the polymer.
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